AlirezaNamiMDFACR

Rheumatology • Charlotte, NC

Lupus & Related, Rheumatoid Arthritis & Related, Spondyloarthropathy

https://www.linkedin.com/in/alireza-nami-md-facr-50676634 http://www.unctv.org/content/healthwise/programs/arthritis

Join to view full profile

Dr. Nami is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Nami's full profile

Already have an account?

Office
332 Lillington Ave
Charlotte, NC 28204
Phone+1 704-377-1216

Summary

Dr. Alireza Nami, based in Charlotte, NC, specializes in Rheumatology with subspecialties in Lupus, Rheumatoid Arthritis, and Spondyloarthropathy. He completed his residency and fellowship at Albany Medical Center and got his degree from St. George's University School of Medicine. He's currently the Principal Investigator and Owner at Joint and Muscle Research Institute and a Principal Investigator at Novant Health Presbyterian Medical Center. He has past experiences as an instructor. He's experienced in treating dermatomyositis and various forms of lupus, and has made significant contributions to clinical trials and research, with published works cited multiple times. He is honored with membership in prestigious organizations and fellowships, such as the American Board of Internal Medicine and the American College of Rheumatology.

Education & Training

Albany Medical CenterFellowship, Rheumatology, 1998 - 2000
Albany Medical CenterResidency, Internal Medicine, 1995 - 1998
St. George's University School of MedicineClass of 1994

Certifications & Licensure

NC State Medical License 2004 - 2025
SC State Medical License 2005 - 2007
AL State Medical License 2000 - 2004
American Board of Internal Medicine Rheumatology
american board of internal MedicineABIM
GCP/ICHGood Clinical Practice

Awards, Honors, & Recognition

American Board of Internal Medicine
Fellow (FACR) American College of Rheumatology
Member EULAR, 2011-2016
International Success in Charlotte, NC, USA CPCC, 2010
Panel Discussion on Arthritis Healthwise Public Television, North Carolina, 2008
Member American Medical Association, 2000
Join now to see all

Clinical Trials

A Study of LY2127399 in Participants With Systemic Lupus Erythematosus Start of enrollment: 2010 Dec 01
Completed
Phase 3
Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (SLE) Start of enrollment: 2010 Dec 01
Completed
Phase 3
Clinical Trial Treatment in Lupus Nephritis Start of enrollment: 2011 Feb 01
Withdrawn
Phase 3
Corrona Rheumatoid Arthritis (RA) Drug Safety & Effectiveness Registry Start of enrollment: 2002 Feb 01
Enrolling by invitation
Subcutaneous Treatment In Randomized Subjects To Evaluate Safety And Efficacy In Generalized Lupus Erythematosus Start of enrollment: 2011 Dec 01
Completed
Phase 2
A Study of the Efficacy and Safety of MEDI-546 in Systemic Lupus Erythematosus Start of enrollment: 2012 Jan 01
Completed
Phase 2
Effectiveness Registry to Study Therapies for Arthritis and Inflammatory Conditions: The Corrona CERTAIN Sub-study Start of enrollment: 2010 Oct 01
Completed
A Study to Assess the Bioequivalence of R406 in Healthy Volunteers When Given 100mg and 150 mg of Fostamatinib Start of enrollment: 2012 Jul 01
Completed
Phase 1
Safety and Effectiveness of BENLYSTA (Belimumab) in Systemic Lupus Erythematosus (SLE) Registry Start of enrollment: 2013 Feb 21
Active, not recruiting
An Open-label Study to Evaluate the Long-term Safety of MEDI-546, for the Treatment of SLE, in Adults Start of enrollment: 2013 Mar 28
Completed
Phase 2
A Non-drug Study Profiling Cutaneous Lupus Start of enrollment: 2013 Apr 01
Completed
A Study to Evaluate Efficacy of Tocilizumab Administered as Monotherapy or in Combination With Methotrexate and/or Other Disease Modifying Antirheumatic Drugs (DMARDs) in Rheumatoid Arthritis (RA) Participants Start of enrollment: 2013 Sep 05
Completed
Phase 3
A Study Investigating the Efficacy and Safety of ABT-494 Given With Methotrexate in Subjects With Rheumatoid Arthritis Who Failed Anti-Tumor Necrosis Factor (TNF) Biologic Therapy Start of enrollment: 2013 Oct 01
Completed
Phase 2
A Study of Tabalumab (LY2127399) Using Two Different Injection Methods in Participants With Lupus Start of enrollment: 2014 Jan 01
Terminated
Phase 3
Efficacy and Safety of Abatacept in Patients With Primary Sjögren's Syndrome Start of enrollment: 2014 Aug 01
Completed
Phase 3
AURA-LV: Aurinia Urinary Protein Reduction Active - Lupus With Voclosporin (AURA-LV) Start of enrollment: 2014 Jun 01
Completed
Phase 2
Study With Etanercept Focusing on Remission and Predictability of Remission in Real Life Clinical Practice Start of enrollment: 2014 Aug 12
Completed
Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus Start of enrollment: 2014 Nov 13
Completed
Phase 2
A Phase 2 Study to Investigate the Safety, Tolerability and Efficacy of ABT-122 in Subjects With Active Psoriatic Arthritis (PsA) Who Have an Inadequate Response to Methotrexate (MTX) Start of enrollment: 2015 Apr 28
Completed
Phase 2
Study of Etanercept Monotherapy vs Methotrexate Monotherapy for Maintenance of Rheumatoid Arthritis Remission Start of enrollment: 2015 Feb 20
Completed
Phase 3
Etanercept and Methotrexate in Combination or as Monotherapy in Psoriatic Arthritis Start of enrollment: 2015 Mar 03
Completed
Phase 3
Efficacy and Safety of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus Start of enrollment: 2015 Jun 09
Completed
Phase 3
A Study of the Efficacy and Safety of Tocilizumab in Participants With Systemic Sclerosis (SSc) Start of enrollment: 2015 Nov 20
Completed
Phase 3
A Study of the Efficacy and Safety of Tocilizumab for Confirmed Rheumatoid Arthritis (RA) Participants in Clinical Practice Start of enrollment: 2017 Jan 26
Terminated
A Study on Rheumatoid Arthritis Patients Treated With Rituximab Start of enrollment: 2008 Apr 01
Completed
Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis Start of enrollment: 2016 Apr 29
Completed
Phase 3
A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis (RA) Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs Start of enrollment: 2016 Mar 22
Completed
Phase 2, Phase 3
A Study to Assess the Efficacy and Safety of AXS-02 in Subjects With Knee OA Associated With Bone Marrow Lesions Start of enrollment: 2016 Mar 01
Active, not recruiting
Phase 3
Long Term Safety of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus Start of enrollment: 2016 Jun 30
Completed
Phase 3
Study to Evaluate BIIB059 (Litifilimab) in Cutaneous Lupus Erythematosus (CLE) With or Without Systemic Lupus Erythematosus (SLE) Start of enrollment: 2016 Oct 20
Completed
Phase 2
Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment Start of enrollment: 2016 Jul 27
Completed
Phase 3
Filgotinib Alone and in Combination With Methotrexate (MTX) in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Are Naive to MTX Therapy Start of enrollment: 2016 Aug 08
Completed
Phase 3
A Study to Characterize the Pharmacokinetics, Pharmacodynamics, and Safety of Anifrolumab in Adult Type I Interferon Test High Systemic Lupus Erythematosus Subject With Active Skin Manifestations Start of enrollment: 2017 Feb 14
Completed
Phase 2
Aurinia Renal Response in Active Lupus With Voclosporin Start of enrollment: 2017 May 17
Completed
Phase 3
Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis Start of enrollment: 2017 Feb 28
Active, not recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE) - BLISS-BELIEVE Start of enrollment: 2018 Mar 01
Completed
Phase 3
Study of BOS161721 in Systemic Lupus Erythematosus (SLE) Patients on a Background of Limited Standard of Care Start of enrollment: 2018 Jan 10
Completed
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

9 citations
Pharmacokinetics, pharmacodynamics, and safety of subcutaneous anifrolumab in patients with systemic lupus erythematosus, active skin disease, and high type I interfer...
Ian N Bruce, Alireza Nami, Erik Schwetje, M Edward Pierson, Tomas Rouse
The Lancet. Rheumatology. 2021-02-01
19 citations
Mortality and adverse events of special interest with intravenous belimumab for adults with active, autoantibody-positive systemic lupus erythematosus (BASE): a multic...
Saira Z Sheikh, Morton A Scheinberg, James Cheng-Chung Wei, Dana Tegzova, William Stohl
The Lancet. Rheumatology. 2021-02-01

Books/Book Chapters

Antioxidants
Alireza Nami, MD

Lectures

GOUT
North Carolina
SLE
NC - 1/1/2016
Therapies in Gouty Arthritis
2010
Small Molecules in treatment of Rheumatoid Arthritis
Rome, Italy - 1/1/2009
TNF inhibitors in Psoriatic Arthritis
2006
Novel treatment options in Rheumatoid Arthritis
Charlotte, NC, USA - 2004
COX-2 inhibition
New York - 4/7/2000
Join now to see all

Authored Content

JMMCRI11/25/2018

Press Mentions

RheumatismJanuary 20th, 2023

Grant Support

ImmunologyPfizer2015–Present

Committees

Fellow, European League of Rheumatism (EULAR) 2011 - Present

Research History

Medical research DirectorPrincipal investigator, and Medical Director at Joint and and muscle research institute conducting clinical trials, phase 23 and 4 and selective phase 0 and 1 studies in rheumatism2000 - 2023